Advances in prevention and health services delivery 2009

Stroke

Volumn 41, Issue 2, 2010, Pages

  Goldstein, Larry B ^a   Rothwell, Peter M ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Angioplasty; Atrial fibrillation; Carotid stenosis; Prevention; Stent; Stroke; Thrombin inhibitors; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CLOPIDOGREL; DABIGATRAN; IRBESARTAN; PLACEBO; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ANTICOAGULATION; CLINICAL TRIAL; DISEASE SEVERITY; HEALTH CARE DELIVERY; HEALTH SERVICE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RISK FACTOR; RISK REDUCTION; SHORT SURVEY; STROKE; THROMBOEMBOLISM; CAROTID ARTERY OBSTRUCTION; METHODOLOGY; OCCLUSIVE CEREBROVASCULAR DISEASE; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; STATISTICS; VASCULAR SURGERY;

ANTICOAGULANTS; CAROTID STENOSIS; DELIVERY OF HEALTH CARE; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTRACRANIAL THROMBOSIS; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; STROKE; VASCULAR SURGICAL PROCEDURES;

EID: 77449129277     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.109.570531     Document Type: Short Survey

References (21)

1. Kettani FZ, Dragomir A, Cote R, Roy L, Berard A, Blais L, Lalonde L, Moreau P, Perreault S. Impact of a better adherence to antihypertensive agents on cerebrovascular disease for primary prevention. Stroke. 2009; 40:213-220.
2. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Stein-berger J, Thom T, Wilson M, Hong Y. Heart disease and stroke statis-tics-2008 update. Circulation. 2008;117:e25-e146.
3. Goldstein LB, Rothwell PM. Advances in prevention and health services delivery 2007. Stroke. 2008;39:258-260.
4. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, Connolly SJ, Dubuc M, Ducharme A, Guerra PG, Hohnloser SH, Lambert J, Le Heuzey JY, O'Hara G, Pedersen OD, Rouleau JL, Singh BN, Stevenson LW, Stevenson WG, Thibault B, Waldo AL. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667-2677.
5. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, Degraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke. 2006;37:1583-1633.
6. Gladstone DJ, Bui E, Fang J, Laupacis A, Lindsay MP, Tu JV, Silver FL, Kapral MK. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke. 2009;40: 235-240.
7. Gattellari M, Worthington J, Zwar N. Warfarin: an inconvenient truth. Stroke. 2009;40:5-7.
8. Hart RG, Pearce LA, Halperin JL, Hylek EM, Albers GW, Anderson DC, Connolly SJ, Friday GH, Gage BF, Go AS, Goldstein LB, Gronseth G, Lip GYH, Sherman DG, Singer DE, van Walraven C. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke. 2008;39:1901-1910
9. The Active Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367: 1903-1912.
10. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med. 2009;360:2066-2078.
11. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
12. Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, Thomas D. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet. 2004;363:1491-1502.
13. Abbott AL. Medical (nonsurgical) intervention alone is now best for prevention of stroke associated with asymptomatic severe carotid stenosis: results of a systematic review and analysis. Stroke. 2009;40: e573-e583.
14. Marquardt L, Geraghty OC, Mehta Z, Rothwell PM. Low risk of ipsi-lateral stroke in patients with asymptomatic carotid stenosis on best medical treatment: prospective population based study. Stroke. 2009. 2010;41: DOI: STROKEAHA.109.561837. Epub November 19, 2009.
15. Brown MM, Ederle J, Bonati LH. Safety results of the International Carotid Stenting Study: Early outcome of patients randomised between carotid stenting and endarterectomy for symptomatic carotid stenosis. European Stroke Conference. 2009. Stockholm, Sweden. May 26-29, 2009.
16. Ederle J, Bonati LH, Dobson J, Featherstone RL, Gaines PA, Beard JD, Venables GS, Markus HS, Clifton A, Sandercock P, Brown MM. Endo-vascular treatment with angioplasty or stenting versus endarterectomy in patients with carotid artery stenosis in the Carotid And Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trial. Lancet Neurol. 2009;8:898-907.
17. Hobson RWI. Update on the Carotid Revascularization Endarterectomy versus Stent Trial (CREST) protocol. J Am Coll Surg. 2002;194:S9-S14.
18. Rothwell PM, Eliasziw M, Gutnikov SA, Fox AJ, Taylor DW, Mayberg MR, Warlow CP, Barnett HJ. Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet. 2003;361:107-116.
19. Cunningham EJ, Bond R, Mehta Z, Mayberg MR, Warlow CP, Rothwell PM. Long-term durability of carotid endarterectomy for symptomatic stenosis and risk factors for late postoperative stroke. Stroke. 2002;33: 2658-2663.
20. Bonati LH, Ederle J, McCabe DJ, Dobson J, Featherstone RL, Gaines PA, Beard JD, Venables GS, Markus HS, Clifton A, Sandercock P, Brown MM. Long-term risk of carotid restenosis in patients randomly assigned to endovascular treatment or endarterectomy in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trial. Lancet Neurol. 2009;8:908-917.
21. Eckstein HH, Ringleb P, Allenberg JR, Berger J, Fraedrich G, Hacke W, Hennerici M, Stingele R, Fiehler J, Zeumer H, Jansen O. Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol. 2008;7:893-902.